At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 66 enrolled
Drug / intervention
Magnesium sulfatedrug
Likely dose
Magnesium sulfate 50 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Magnesium Sulfate as Adjuvant Analgesia and Its Effect on Opiate Use of Post-operative Transplant Patients in the Pediatric ICU
In Brief
A Phase 2 clinical trial evaluating Magnesium sulfate for Postoperative Pain. Completed, enrolled 66 participants across 1 site.
Detailed Summary
To use magnesium sulfate as adjuvant analgesia by implementing a treatment protocol in order to determine whether can benefit pediatric pain in post-operative transplanted patients and decrease overall opioid consumption.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPostoperative Pain
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
Enrollment StartMar 2021
First PostedMar 2021
Primary CompletionAug 2023
TodayJul 2026
First PostedMar 23, 2021
Enrollment StartMar 1, 2021
Primary CompletionAug 10, 2023
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 5.3 years ago
Interventions
Magnesium sulfatedrug
Magnesium sulfate (MgSO4) will be administered intravenously at induction of anesthesia as a 30-minute bolus dose of 50 mg/kg (maximum 2 grams) in the OR, followed by a 15 mg/kg/hr IV infusion for 48 hours or once the patient has transferred out of the PICU, whichever comes first.